Loading news...
Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Connective Portfolio Management LLC bought a new stake in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,500 shares of the company's stock, valued at approximately $805,000. Legend Biotech makes
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival (mPFS) of 50.4 months was observed following a single infusion of CARVYKTI®. This represents one of the longest PFS outcomes reported for a BCMA-targeted CAR-T cell therapy in this heavily pretreated population.
Ensign Peak Advisors Inc trimmed its position in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 30.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,300 shares of the company's stock after selling 2,750 shares during the
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its growing sales is its superior efficacy compared to Elrexfio, Abecma, and Tecvayli.
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang - President of Research & Development Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Terence Flynn - Morgan Stanley, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division James Shin - Deutsche Bank AG, Research Division Justin Zelin - BTIG, LLC, Research Division Katherine Degen Ashwani Verma - UBS Investment Bank, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's Third Quarter 2025 Earnings Call.
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 67th Annual American Society of Hematology (ASH) Annual Meeting taking place from December 6-9, 2025, in Orlando, FL.
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.
The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal gastrointestinal condition.
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue share outside China. Despite >$1bn cash and operational improvements, Legend remains unprofitable, with heavy GAAP losses and apparently no formal guidance for 2025.
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Alan S. Bash - President of CARVYKTI® Caroline LeCates Paul - Associate Director of Investor Relations Jessie Yeung - Interim CFO, Principal Financial Officer & Principal Accounting Officer Mythili Koneru - Chief Medical Officer Ying Huang - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division James John Shin - Deutsche Bank AG, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Leonid Timashev - RBC Capital Markets, Research Division Mitchell Swaroop Kapoor - H.C.
Key Inflation Data in Focus.